Novel PET Radiotracers for Potential Use in Management of Lymphoma.

This article discusses possible roles for emerging novel positron emission tomography (PET) radiotracers for diagnosis and follow-up of lymphomas. Novel imaging probes are being developed to fulfill the need of a more specific radiopharmaceutical to target subcomponents of tumor microenvironment to individualize management approaches. Noninvasive molecular imaging probes are being developed to revolutionize characterization of tumor biology and response to therapy in more specific ways for the host, tumor microenvironment, and therapeutic regimens. The new clinical PET probes seem promising in fostering clinical gains that would lead to better survival outcomes, although further studies are warranted to prove a role in the management of lymphomas.